Related Experiment Video

Updated: Mar 12, 2026

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

15.1K

Improving treatment of liver metastases by targeting nonangiogenic mechanisms

Kyrre E Emblem1, Rakesh K Jain2

  • 1Department of Diagnostic Physics, The Intervention Centre, Oslo University Hospital, Oslo, Norway.

Nature Medicine
|November 9, 2016
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

14.0K
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.6K

Related Experiment Videos

Last Updated: Mar 12, 2026

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

15.1K
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

14.0K
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K

Articles linked to this work by shared authors, journal, and citation graph.

Mapping radiosensitivity in glioblastoma using MR elastography and biomechanical modeling.

Scientific reports·2026

Automated delineation of putative non-contrast-enhancing tumor in glioblastoma: Prognostic insights.

Neuro-oncology·2026

Biomechanical mapping of tumor growth: A novel method to quantify glioma infiltration and mass effect.

Medical physics·2026

Comparing Glymphatic Function Measures: Diffusion Tensor Image Analysis Along Perivascular Spaces (DTI-ALPS) versus Intrathecal Contrast-Enhanced MRI.

Radiology·2026

Modeling glioma-induced impairments on the glymphatic system.

Fluids and barriers of the CNS·2026

Standardized evaluation of the extent of resection in glioblastoma with automated early post-operative segmentation.

Frontiers in radiology·2024

An open vision-language model for diverse medical applications.

Nature medicine·2026

Extended follow-up of in vivo BCMA CAR-T therapy in relapsed/refractory multiple myeloma.

Nature medicine·2026

Oral small-molecule GLP-1RA safiglipron versus dapagliflozin in type 2 diabetes: a randomized, double-blind, active-comparator-controlled phase 3 trial.

Nature medicine·2026

Global and regional reference curves for pain across the lifespan in 6.1 million individuals in 118 countries.

Nature medicine·2026

Urine cell-free RNA for bladder cancer detection and treatment response prediction.

Nature medicine·2026

Small quantity lipid-based nutritional supplementation and measles vaccination coverage in children aged 6-23 months: a pragmatic cluster-randomized trial.

Nature medicine·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us